|
Last
updated February 10, 2005
Saturday, MAY 14
10:00am–12:00pm
4300—Development
of Hypertension in the Newborn: Translating Theory into
Practical Application
PAS/IPHA Topic Symposium
Chairs:
Elaine Urbina, Children's Hospital Medical Center,
Cincinnati, OH; and Luc Brion, Montefiore Medical Center,
Bronx, NY
Hypertension is found in up to 2% of term or preterm
neonates. The prevalence is difficult to ascertain
precisely since the definition of hypertension in this age
group has not been completely standardized. However,
recent studies have provided normative data that may be
useful in identifying these infants. This symposium will
examine key aspects of the diagnosis of hypertension in
the neonate including measurement and instrumentation
issues and normal values. Pre- and post-natal risk factors
for the development of neonatal hypertension will be
addressed along with treatment options. Perinatal
programming for future cardiovascular disease will also be
addressed.
Target Audience: Neonatologists, pediatric
nephrologists, pediatric cardiologists, general
pediatricians
How Do We Measure BP in the Neonate and What Is
Normal?
Alan
Zubrow, Drexel University College of Medicine, St.
Christopher's Hospital for Children, Philadelphia, PA
How Does “Perinatal Programming” Contribute to
the Development of Subsequent Vascular Disease?
Julie
R. Ingelfinger, Massachusetts General Hospital, Boston, MA
Perinatal Influences on Blood Pressure In the Newborn
Matthew
W. Gillman, Harvard Medical School/Harvard Pilgrim Health
Care, Boston, MA
What Non-pharmacologic and Drug Treatment Options Are
Available for the Management of Neonatal Hypertension
Douglas
L. Blowey, Children's Mercy Hospitals and Clinics, Kansas
City, MO
Sponsored jointly by the International
Pediatric Hypertension Association and the Pediatric
Academic Societies
11:45am–2:45pm
4501—Fish,
Worms and Flies
PAS Mini Course
Chair:
Edward R.B. McCabe, Mattel Children's Hospital at UCLA,
Los Angeles, CA
One of the most important lessons of the Human Genome
Project is how similar we are to the organisms that
surround us. The similarities between our biology and
theirs means that they truly are models from which we
learn more about ourselves and our diseases. In this mini
course, we will see how the fruit fly, Drosophila
melanogaster, can be used to identify drugs for human
diseases. We will learn how the nematode worm,
Caenorhabditis elegans, can be used to investigate
signaling pathways that are preserved from worms to humans
and are critical to committing undifferentiated cells to
differentiate correctly. The zebrafish, Danio rerio,
provides us with a vertebrate model for studying organ
systems similar to our own. The presenters will provide a
general overview of their organism and then an in-depth
description of their research.
Target Audience: Investigators involved with or
interested in learning about research involving model
organisms. Appeal will be the strengths of these
non-mammalian models for investigations ranging from
developmental biology to high-throughput drug screens.
Overview of Non-mammalian Model Organisms
Edward
R.B. McCabe, Mattel Children's Hospital at UCLA, Los
Angeles, CA
Flies: Identifying New Drugs for Human Diseases
Juan
Botas, Baylor College of Medicine, Houston, TX
Worms: Signal Transduction and Cellular
Differentiation
David
M. Eisenmann, University of Maryland, Baltimore, MD
Fish: Developmental Genetics of the Heart
Didier
Stainier, University of California, San Francisco, CA
Discussion
Sponsored jointly by the AAP Section on
Cardiology and the Pediatric Academic Societies
1:00pm–3:00pm
4600A—Urolithiasis
and Mineral Metabolism
ASPN Symposium
Chairs:
Uri S. Alon, Children's Mercy Hospital, Kansas City, MO;
and Dawn S. Milliner, Mayo Clinic, Rochester, MN
The symposium will address new findings and
developments in our understanding of phosphate homeostasis
in health and disease. Genetic, environmental and
idopathic etiologies of pediatric urolithiasis will be
discussed, as well as medical means and urological
techniques utilized in the management of kidney stone
disease.
Target Audience: Scientists and clinicians involved
with pediatric mineral metabolism and kidney stone
disease.
New Insights into the Regulation of Phosphate
Metabolism
Anthony
A. Portale, University of California, San Francisco, CA
Pediatric Clinical Trials with Intravenous Vitamin D
Analogs
Laurence
Greenbaum, Medical College of Wisconsin, Milwaukee, WI
Genetic Basis of Stone Forming Disease
Dawn
S. Milliner, Mayo Clinic, Rochester, MN
Idiopathic Calcium Stones
Uri
S. Alon, Children's Mercy Hospital, Kansas City, MO
Urologic Intervention in Children with Urolithiasis
Jeffrey
S. Palmer, Rainbow Babies and Children's Hospital,
Cleveland, OH
Discussion
1:00pm–3:00pm
4650—ADHD:
Issues In Management
PAS Original Science Abstracts -
Platform Session
Sunday, MAY 15
8:00am–10:00am
5146—Neonatal
CNS Injury
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
5147—Oxidant
Signaling Pathways
PAS Original Science Abstracts -
Poster Symposium
8:00am–11:00am
5200—ADHD
and Other Disruptive Behaviors in Preschool Children:
Challenges in Diagnosis and Treatment
PAS Mini Course
Chair:
Martin T. Stein, University of California San Diego, San
Diego, CA
Pediatricians typically think about ADHD as a
neurobehavioral condition in school-age children and
adolescents. In preschool children, evidenced-based
studies on diagnosis and treatment of ADHD are limited. In
young children, it is especially difficult to distinguish
hyperactivity, impulsive behaviors and inattention from
developmentally normal behavior in this age group. The
session will begin with a discussion about a
developmental–biopsychosocial model for early
identification and treatment of attentional and disruptive
disorders in young children. Recent studies designed to
define an evidenced-based structure for the diagnosis and
treatment of ADHD in young children will be reviewed.
Current knowledge about the effectiveness of behavior
management, parent training and psychopharmacological
treatments in preschool children with ADHD will be
emphasized. The symposium will target the clinical
challenges of working with preschool children who present
with ADHD-like behaviors in pediatric practice.
Target Audience: Clinicians who see preschool
children and teachers of pediatric residents and medical
students; those who do research in developmental and
behavioral pediatrics and pediatric neurology; clinicians
who want to find direction in evaluating and managing
hyperactive, disruptive and impulsive preschool children;
and to clinicians and those who study disruptive behaviors
in preschool children.
ADHD in Preschool Children: Challenges in Definition,
Diagnosis and Treatment
Martin
T. Stein, University of California San Diego, San Diego,
CA
Developmental–Biopsychosocial Model for Early
Identification and Comprehensive Treatment of Attentional
and Disruptive Disorders in Young Children
Stanley
I. Greenspan, George Washington University School of
Medicine, Washington, DC
Diagnostic Strategies for ADHD in Preschool Children
Helen
Link Egger, Duke University Medical Center, Durham, NC
Treatment of Disruptive Behaviors in Preschool
Children
Chris
K. Varley, University of Washington Medical Center,
Children's Hospital and Regional Medical Center, Seattle,
WA
The Preschool ADHD Treatment Study (PATS Study)
Larry
L. Greenhill, New York State Psychiatric Institute, New
York, NY
Managing Disruptive Preschool Children with ADHD in a
Pediatric Office
Suzanne
Dixon, University of Washington, University of California
San Diego, Emeritus
Discussion
2:00pm–4:00pm
5535—Neonatal
Epidemiology and Follow-up
PAS Original Science Abstracts -
Platform Session
2:00pm–4:00pm
5538—Pathogenesis,
Prevention and Treatment of Necrotizing Enterocolitis
PAS Original Science Abstracts -
Poster Symposium
2:00pm–5:00pm
5561—Pediatric
Neuropharmacology—Current Controversies
PAS Mini Course
Chair:
Faye Silverstein, University of Michigan, Ann Arbor, MI
This mini course will highlight issues of interest to
many pediatricians. Neuroactive drugs are used to treat a
wide range of neurological and behavioral disorders in
children and adolescents. Often, these drugs have not been
systematically evaluated in this age group, and the issue
of “off-label” use of neuroactive drugs has recently
received considerable national attention.
We have recruited five experts in pediatric
therapeutics for this mini course. Four will discuss
treatment issues, and the fifth will discuss ethical
issues that must be considered in pediatric drug testing.
Graham Emslie will discuss the safety and efficacy of
selective serotonin release inhibitors (SSRIs) in children
and adolescents with depression and related disorders. The
controversies regarding the use of these agents in the
pediatric age group have raised important questions for
all pediatricians. He will also highlight important
questions for future research to improve clinical outcomes
of children with psychological disorders.
James McCracken will provide his perspective on the
use of second generation antipsychotics in children and
adolescents. These drugs are widely used to treat a broad
range of behavioral disorders. He will review current
information about the efficacy and tolerability of these
drugs and suggest guidelines for clinical monitoring.
Carter Snead will provide his perspective on the
roles of the new generation of anti-convulsant drugs
(introduced over the past 10 years) in the treatment of
childhood epilepsy. He will discuss some of the drugs that
have already gained widespread usage in children and
discuss their potential risks and benefits.
Judith Owens will discuss current approaches to drug
therapy of pediatric sleep disorders. As new drug
therapies are introduced, both to induce sleep and to
sustain wakefulness, it is likely that their use will
extend to children and adolescents. The diagnosis of sleep
disorders is rapidly increasing in children, and Dr. Owens
will discuss major diagnostic and therapeutic issues.
Joel Frader will discuss ethical issues in pediatric
drug testing. His topics will include: who should give
“consent” for study participation, the circumstances
permitting placebo controls, implications of FDA and/or
NIH incentives/mandates for pediatric testing, conflicts
between care giving and researcher roles, obligations to
provide study results to participants and special
considerations for phase I testing.
Target Audience: Broad range of clinicians who treat
children with neurological and psychological disorders.
Introduction
Faye
S. Silverstein, University of Michigan, Ann Arbor, MI
SSRIs in Pediatrics: What Do We Really Know?
Graham
Emslie, University of Texas–Southwestern Medical Center,
Dallas, TX
Promises and Pitfalls of Newer Antipsychotics in
Children and Adolescents
James
McCracken, UCLA Neuropsychiatric Institute, Los Angeles,
CA
New Anticonvulsants—Roles in Treatment of Childhood
Epilepsy
O.
Carter Snead, The Hospital for Sick Children, University
of Toronto, Toronto, Canada
Drug Therapy of Pediatric Sleep Disorders
Judith
A. Owens, Brown University, Providence, RI
Pediatric Drug Testing: Ethical Considerations
Joel
E. Frader, Children's Memorial Hospital, Chicago, IL
Discussion
4:15pm–5:45pm
5702—Identification
of Asthma-Susceptibility Genes and Implications for New
Pharmaceutical Development
PAS State of the Art Plenary
Chair:
Clifford W. Bogue, Yale University School of Medicine, New
Haven, CT
Asthma is rapidly emerging as a major public health
disorder in childhood. Innovative strategies combining
genetic mapping and gene expression profiling are
providing the tools to identify genes that underpin asthma
predisposition. This presentation not only has relevance
for an important pediatric medical topic, but also
establishes a paradigm that can be used for other complex
genetic disorders that affect children.
Target Audience: This session will be of interest to
a broad audience including practicing pediatricians,
geneticists, pulmonologists, pharmacologists, critical
care specialists and allergist/immunologists
Marsha Wills-Karp, Children's Hospital Medical
Center, Cincinnati, OH
Monday, MAY 16
8:00am–10:00am
6132—Clinical
Trials in Perinatal and Neonatal Medicine I
PAS Original Science Abstracts -
Platform Session
3:00pm–5:00pm
6702—Neonatal
Neuropharmacology in 2005
PAS Topic Symposium
Chair:
Faye Silverstein, University of Michigan, Ann Arbor, MI
A critical priority for neonatal medicine is the
challenge of understanding the impact of diverse forms of
therapy on brain development. It remains extremely
challenging to design feasible studies to address this
theme. In infants with underlying neurological disorders
it is particularly difficult to distinguish whether
long-term adverse effects reflect underlying
neuropathology or deleterious effects of a specific
therapy. The three speakers will provide an overview of
current and future approaches to treat the major
neurological disorders that affect neonates and how the
risks and benefits of treatment can be dissected.
Donna Ferriero will discuss current strategies for
selection of neonates for neuroprotection therapy and new
approaches for the development of more effective
neuroprotection interventions. She will discuss mechanisms
of brain injury and repair that are unique to the
developing brain. She will highlight the scientific
rationale for development of combination therapies that
may be most successful in protecting the injured neonatal
brain.
Scott Rivkees will highlight new information about
adenosine pharmacology in the neonatal brain. Caffeine is
a multifunctional drug that blocks adenosine action. High
doses of caffeine exert adverse effects on the developing
brain; however, recent evidence suggests that blocking
adenosine action may reduce certain forms of brain injury
in experimental models. His talk will address influences
of caffeine action and adenosine blockade during
development.
Faye Silverstein will discuss information about the
current treatment of neonatal seizures and strategies for
improving diagnosis and treatment. Her talk will highlight
some of the major unanswered questions about diagnosis and
treatment of neonatal seizures. She will also discuss the
implications of recent basic science findings regarding
risks of anti-convulsant therapy in the developing brain.
Target Audience: Clinicians involved in the treatment
of neonates with neurological disorders and scientists
interested in mechanisms of neonatal brain injury and
repair.
Introduction
Faye
S. Silverstein, University of Michigan, Ann Arbor, MI
Neonatal Neuroprotection: Cocktails and Ice
Donna
M. Ferriero, University of California, San Francisco, CA
Effects of Caffeine and Other Adenosine Antagonists
on Brain Development
Scott
A. Rivkees, Yale School of Medicine, New Haven, CT
Neonatal Seizures: How Can Treatment Be Improved?
Faye
S. Silverstein, University of Michigan, Ann Arbor, MI
Discussion
3:00pm–5:00pm
6735—Pharmacology
PAS Original Science Abstracts -
Platform Session
3:00pm–5:00pm
6736—Placental
Biology
PAS Original Science Abstracts -
Poster Symposium
5:15pm–6:45pm
Poster
Session III
PAS Original Science Abstracts -
Poster Session
Pharmacology:
6840—Clinical Applications
6841—Basic Insights
Tuesday, MAY 17
8:00am–10:00am
7152—Clinical
Trials in Perinatal and Neonatal Medicine II
PAS Original Science Abstracts -
Platform Session
1:45pm–3:45pm
7601—New
Therapeutic Strategies for Classical Pediatric Diseases
PAS Hot Topic
Chairs:
David Cornfield, University of Minnesota School of
Medicine, Minneapolis, MN; and Nina F. Schor, Children's
Hospital of Pittsburgh, Pittsburgh, PA
The pathogenesis of numerous single-gene disorders
has been effectively delineated. However, the application
of this knowledge to patient care has lagged far behind.
This symposium will present recent progress made in the
development of therapeutic strategies for four classical
pediatric disorders. First, novel genetic therapies for
hematologic diseases will be discussed. Second,
interventions that reverse the key abnormalities in signal
transduction underlying autosomal dominant polycystic
kidney disease, a leading cause of end-stage renal
disease, will be presented. Third, we will discuss a
treatment strategy that normalizes the intracellular
processing and function of the mutated cystic fibrosis
transmembrane conductance regulator (CFTR), which
underlies the majority of cases of CF. Fourth,
pharmacologic strategies against muscular dystrophy will
be presented. These four innovative approaches provide
great hope for patients suffering from these disorders,
and they serve as exciting examples of potential means to
combat other devastating pediatric conditions.
Target Audience: Scientists and clinicians involved
with the development of new therapeutic strategies for a
variety of childhood disorders.
Embryonic Globins as Therapeutic Agents for
Hemoglobinopathies and Thalassemias
J.
Eric Russell, The Children's Hospital of Philadelphia,
Philadelphia, PA
Novel Therapies for Renal Cystic Diseases
Vicente
E. Torres, Mayo Clinic, Rochester, MN
Treatment of Cystic Fibrosis with Curcumin
Marie
E. Egan, Yale University School of Medicine, New Haven, CT
Pharmacologic Strategies Against Muscular Dystrophy
Tejvir
S. Khurana, University of Pennsylvania School of Medicine,
Philadelphia, PA
|
